However, as macular thickness and not the occurrence of the new blood vessels serves as a surrogate parameter of anti-VEGF-A treatments in the human condition, it is likely that also in the treatment of patients with AMD the decision bases on a parameter that is stronger linked to inflammation than on angiogenesis. Here, VEGFA is linked to age-related macular degeneration.